Jiangsu Kanion Pharmaceutical News

Kangyuan Pharmaceutical (600557): A leader in innovative traditional Chinese medicine that is expected to gradually reverse

浙商證券May 12 00:00

Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross mar

Zhitong FinanceApr 19 13:19

Kangyuan Pharmaceutical (600557) Review Report: Outstanding Performance of Oral Medications, Cost Optimization

萬聯證券Apr 19 13:16

China Post Securities released a research report on April 17 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) revenue: rapid growth in oral liquid, slight decline in injections due t

Zhitong FinanceApr 17 09:18

Kangyuan Pharmaceutical (600557): Recovery of oral formulations with excellent report quality

中信建投證券Apr 16 08:21

Kangyuan Pharmaceutical (600557): 2024Q1 oral liquid regains rapid growth, steady profitability, and operational efficiency optimization

中郵證券Apr 16 00:00

On April 15, Dongfang Wealth Securities released a research report stating that Kangyuan Pharmaceutical (600557.SH) was given an increase in its holdings rating. The main reasons for the rating include: 1) performance continues to grow under a high base;

Zhitong FinanceApr 15 16:48

Huafu Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 28 yuan. The main reasons for the rating include: 1) achieving positive growth under the high Q1

Zhitong FinanceApr 15 08:46

Guolian Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 25.72 yuan. The main reasons for the rating include: 1) Jin Zhen oral liquid and muscle pain re

Zhitong FinanceApr 14 18:03

Kangyuan Pharmaceutical (600557): Maintaining positive growth under a high base, oral liquid performed well

華福證券Apr 14 00:00

Kangyuan Pharmaceutical (600557): The oral solution that met expectations performed well

浙商證券Apr 13 00:00

Kangyuan Pharmaceutical (600557): Rapid performance growth in 23 years, non-injectable dosage can be expected in 24 years

華福證券Mar 19 07:36

Kangyuan Pharmaceutical (600557): Steady growth, net profit to mother increased by 23.54% for the full year of '23

國信證券Mar 15 16:11

Kangyuan Pharmaceutical (600557): Outstanding profit performance and significant improvement in operating efficiency

招商證券Mar 15 00:00

Kangyuan Pharmaceutical (600557) 2023 Annual Report Review Report: 2023 Q4 profit exceeds expectations, and performance is expected to return to steady

國海證券Mar 13 00:00

Kangyuan Pharmaceutical (600557): Injectables are growing strongly, marketing is increasing, and non-injectables are expected to resume relatively rapid growth

中郵證券Mar 13 00:00

Kangyuan Pharmaceutical (600557): Excellent profit side performance, academic transformation is expected to continue to boost performance

東吳證券Mar 12 12:36

Kangyuan Pharmaceutical (600557): Injection varieties drive growth, oral varieties promote specialization

海通證券Mar 12 07:21

Kangyuan Pharmaceutical (600557): Outstanding performance, driving the increase in non-injectable varieties in 24 years

信達證券Mar 11 19:26

Kangyuan Pharmaceutical (600557) Company Information Update Report: Daconine injections contributed to impressive performance, and marketing reforms continued to break the game

開源證券Mar 11 16:41